This study uncovers the mechanism by which BYHWD improves cognitive deficits and neuropathological changes in 3×Tg mice via the gut–brain axis, mediated by the modulation of the gut microbiota‐C/EBPβ/AEP signaling pathway, providing a novel therapeutic strategy for AD. This evidence concerns the gene LGMN and Alzheimer disease.